Patient-specific biokinetics and hybrid 2D/3D approach integration in OEDIPE software: Application to radioiodine therapy

Targeted radionuclide therapy (TRT) has demonstrated its clinical efficacy in treating malignant or benign thyroid disease with iodine-131 (I-131) [1 –3]. In addition to I-131, Y-90 microspheres are increasingly used for the treatment of liver cancers, as well as Lu-177 coupled with different tumour-specific vectors [4]. The clinical application of TRT with I-131 is commonly based on the administration of a fixed activity, regardless of the pat ient-specific biokinetics of the radiopharmaceutical, which could lead to an underdose preventing tumor control, or an overdose that may induce toxicity to the organs at risk [5].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Technical note Source Type: research